[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）.实用肝脏病杂志,2011,14（2）：81-89.
[2] Lok AS,McMahon BJ. Chronic hepatitis B. Hepatology,2007,45:507-539.
[3] Hoofnagle JH,Doo E,Liang TJ,et al. Management of hepatitis B：summary of a clinical research workshop. Hepatology,2007,45:1056-1075.
[4] Zeuzem S,Buti M,Gane E,et al. Baseline parameters predict both early virological response and longer term outcomes for telbivudine treated patients with chronic hepatitis B（the GLOBE study）. Hepatology,2007,46（Suppl 1）:681A.
[5] 祝卫东,陈良云,陈俊飞,等. 恩替卡韦治疗失代偿期乙型肝炎肝硬化临床观察. 肝脏,2010,15（2）：87-89.
[6] 林青,张大志,周智,等. 恩替卡韦与阿德福韦治疗慢性乙型肝炎患者48周的临床疗效观察.中华肝脏病杂志,2010,18（5）：338-341.
[7] 罗红彬,胡中伟,郭家伟. 恩替卡韦治疗失代偿期乙型肝炎肝硬化48周疗效观察. 实用肝脏病杂志,2009,12（2）：121-123.
[8] 郭西萍,王婉,张继红,等. 恩替卡韦联合络舒肝胶囊治疗活动性乙型肝炎肝硬化的疗效平价. 实用肝脏病杂志,2009,12（2）：124-126.
[9] Colonno RJ,Rose R,Baldick CJ,et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology,2006,44:1656-1665.
[10] Chang TT,Gish RG,Hadziyannis SJ,et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology,2005,129：1198-1209.
[11] Sherman M,Yurdaydin C,Sollano J,et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine refractory HBeAg（+）chronic hepatitis B：resuilts in phase III study ETV-026.Hepatology,2004,40 Suppl 1:664A.
[12] 忠英,乔逸,贾艳艳,等. 对恩替卡韦分散片的人体生物等效性研究.药物服务与研究,2010,10（5）：374-376.
（校对：陈宗炳） |
